Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,669 recruiting studies in this area right now.
By phase
- Not applicable9,830
- Phase 24,462
- Phase 12,741
- Phase 1/Phase 21,687
- Phase 31,405
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer659
- Prostate Cancer657
- Colorectal Cancer496
- Lung Cancer428
- Ovarian Cancer338
- Multiple Myeloma329
- Gastric Cancer300
- Pancreatic Cancer296
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer232
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors195
- Esophageal Cancer193
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University311
- Memorial Sloan Kettering Cancer Center289
- Sun Yat-sen University289
- National Cancer Institute (NCI)288
- Mayo Clinic238
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto125
Where studies are running
- California1,425
- Texas641
- Arizona513
- Florida446
- Alabama420
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania241
Recruiting studies20,669 total
- NCT05371132RecruitingPhase 1
PET scan study to track immune response after SBRT
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Duarte, CaliforniaAges 18 years+ - NCT05371353Recruiting
Study of how long HPV vaccine immunity lasts
This study checks how well the HPV (cancer-preventing) vaccine protection stays in your body over time. It may help confirm the vaccine’s “long-lasting” immune response and guide future vaccination confidence.
Yangchun, GuangdongAges 9–45 - NCT05371756Recruiting
Bio sample collection study for people at risk of cancer
This study collects blood (and other biospecimens) to look for immune and molecular markers that may help explain cancer risk or response to treatment. If you’re an adult whose provider thinks you could develop cancer, or who has confirmed/suspected cancer, you may be asked for samples and consent to help researchers.
College Station, TexasAges 18 years+ - NCT05372354RecruitingPhase 1/Phase 2
Testing a new multiple myeloma drug with other treatments
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
Birmingham, AlabamaAges 18 years+ - NCT05372484Recruiting
Test technology to improve cervical cancer screening and diagnosis
This study tests a new technology to help find cervical cancer earlier by focusing on people who already had an abnormal screening result. It may help improve how abnormal tests are checked and diagnosed.
Houston, TexasAges 25–49 - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05373823Recruiting
Online skin check coaching for melanoma survivors
This study tests an online program to help melanoma survivors do full-body skin self-checks regularly. It may help you catch new or changing skin areas earlier by improving how often and how thoroughly you check.
New Brunswick, New JerseyAges 18 years+ - NCT05373810Recruiting
Study for people with bone or soft tissue sarcoma
This study is for people who have been diagnosed with bone or soft tissue sarcoma confirmed by a tissue test. It may help researchers understand sarcoma better, but you must be able to understand and consent to take part.
ArnhemAges 18 years+ - NCT05375591Recruiting
AI study to sort lung nodules after past cancer treatment
This study uses computer tools (AI) and detailed scan patterns to better classify new lung nodules in people who previously had curative-intent cancer treatment. It may help doctors decide whether a nodule is likely benign or cancer, using your CT scan and related medical history.
LondonAges 18 years+ - NCT05375266Recruiting
Study of immune signals in head and neck cancer
This study looks at “immune signals” in blood, saliva, and stool to learn more about head and neck cancers (especially squamous cell carcinoma). It may help researchers find patterns that improve understanding of disease or how treatment should be guided.
Erlangen, BavariaAges 18 years+ - NCT05375617Recruiting
Study for newly diagnosed childhood cancers in Europe
This study follows children and teens with newly diagnosed certain leukemia (ALL) and certain favorable brain tumors to learn best care and outcomes. It may help your team compare standard treatments and monitor health over time.
New York, New YorkAges 3–21 - NCT05375370Recruiting
Testing a blood test to predict liver cancer coming back
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
RouenAges 18 years+ - NCT05376111RecruitingPhase 2
Venetoclax plus azacitidine for newly diagnosed T-ALL
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
Suzhou, JiangsuAges 15 years+ - NCT05377034RecruitingPhase 2
Y-90 and immunotherapy vs Y-90 plus placebo for liver cancer
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
BeijingAges 21–99 - NCT05376592Recruiting
Study genes and weight loss in pancreatic cancer
This study looks at how a person’s genetic variations may relate to cancer-related weight loss (cachexia) in pancreatic cancer. It may help researchers better understand who is most at risk and guide future treatments.
Charlotte, North CarolinaAges 18 years+ - NCT05377658RecruitingPhase 2
AK104 with chemo before and after surgery for lung cancer
This trial studies AK104 along with chemotherapy given before surgery and after surgery for people with resectable (operable) stage II to IIIA non-small cell lung cancer. It aims to improve treatment effectiveness by shrinking the tumor before surgery and helping prevent it from coming back afterward.
Zhengzhou, HenanAges 18–75 - NCT05377307Recruiting
Long-term follow-up for gene-edited immune cell therapy
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Kaohsiung, TaiwanAges Any age - NCT05378204Recruiting
Testing DNA repair marker for PARP inhibitor resistance
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
BordeauxAges 18 years+ - NCT05378139Recruiting
At-home and hospital wireless monitoring for worsening health
This trial tests a system that continuously checks vital signs (like heart rate and breathing) using wireless sensors and sends automatic alerts if you seem to be getting worse. It may help clinicians spot problems sooner whether you’re being monitored at home or around a major surgery hospital stay.
Copenhagen, CopenhagenAges 18 years+ - NCT05378334Recruiting
Test herbal treatment for lung cancer spread to bone
This trial studies whether the herbal medicine HGXJT can improve outcomes and safety for people with non-small cell lung cancer that has spread to the bones. It is designed for a specific lung cancer type (EGFR and ALK wild type) and people who have not had certain immune treatments before.
Guangzhou, GuangdongAges 18–75 - NCT05378633Recruiting
CyberKnife treatment for multiple brain metastases
This trial looks at how well (and how much) CyberKnife radiation works for people with multiple brain metastases. It may help your care team understand the best way to treat several brain spots safely.
HeidelbergAges 18 years+ - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Birmingham, AlabamaAges 18 years+ - NCT05379803RecruitingPhase 2
High-dose furmonertinib for lung cancer with brain metastases
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
Changsha, HunanAges 18 years+ - NCT05379738Recruiting
Exercise program to aid recovery after donor stem cell transplant
This trial tests whether an adapted physical activity (tailored exercise) can help people recover after a donor stem cell transplant for blood cancers. If you’re able to participate, the program may support strength, well-being, and recovery during the transplant process.
NiceAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,669 recruiting oncology studies from the U.S. registry right now, out of 31,797 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.